Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ORGANIZATION
ORGANIZATION
- NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
February 10, 2012
- MHLW “Missing the Bigger Picture” in Measures to Eliminate Drug Lag: Prof. Nakamura
February 10, 2012
- PhRMA Concerned that Health Economic Evaluation Will Be Used to Reduce NHI Prices: Mr Zulueta
February 6, 2012
- JACDS to Strengthen Support to Ensure Compliance in Sale of OTC Drugs
February 6, 2012
- It Is Difficult to Check Off-Label Use of Generics Approved for Indications Different from Those of Original Drugs: Medical Bill Payment Fund
February 1, 2012
- JPMA to Make Proposals on Pricing of Long-Listed Drugs to CSIMC: President Teshirogi
January 31, 2012
- BG Kansai to Establish Service Hub to Support Use of Supercomputers in Drug Discovery
January 31, 2012
- MHLW, JPWA Hold Public-Private Dialogue on Distribution Improvement
January 30, 2012
- JPWA Board of Directors Approve By-Category Talks to Be Common Understanding
January 27, 2012
- JPA Supports Ban on “Dispensing Point” Services at Pharmacies
January 26, 2012
- JSMI to Seek Expansions of OTCs by Appealing Preventive Effects in 2012
January 24, 2012
- JPMA to Focus on Thorough Enforcement of Compliance in Next Fiscal Year
January 20, 2012
- JPMA to Discuss State of Long-Listed Products Over a Year Ahead of FY2014 Revision
January 19, 2012
- JPMA to Set Transparency Guideline for Relationships with Patient Organizations, Disclose Information from FY2013
January 19, 2012
- JPWA, NPhA Hold Talks for Distribution Improvement
January 18, 2012
- FPMAJ Detects Radioactive Substances in 2 Crude Raw Material Samples
January 17, 2012
- JGA President Sawai Says Members United to Provide Stable Drug Supplies to Meet Boosted Demand
January 13, 2012
- JPWA President Bessho Expresses Resolve for Distribution Improvement
January 12, 2012
- PMAT President Matsuda Says Permanent Introduction of Premium is Priority Issue
January 10, 2012
- FPMAJ Chairman Pledges Further Efforts for Permanent Introduction of Premium, Caution Towards Additional Price Cuts Becoming Rule
January 5, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…